Zacks' 7 Best Stocks for July, 2013
FREE Report for Zacks.com
Visitors Only

They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.

Today, you can see them free.

Close This Panel X

Are you a new Zacks Member or a visitor to Zacks.com?

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Stocks on the Move 06/19/2013

Company Name Symbol %Change
SONIC FOUNDR SOFO
4.40%
SUPPORT.COM SPRT
3.75%
UNISYS UIS
3.31%
SHORETEL INC SHOR
3.22%
GREEN MTN CO GMCR
3.13%

Humana Closes Arcadian Purchase

by Zacks Equity Research

April 04, 2012 | Comments : 0 Recommended this article: (0)

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

On Monday, Humana Inc. (HUM - Analyst Report) announced that it has completed the acquisition of Arcadian Management Services, a Medicare Advantage health maintenance organization. The financial and other terms of this deal were not divulged. The takeover is not expected to impact Humana’s earnings in 2012.

The deal, which was initially announced in August 2011, obtained anti-trust approval from the U.S. Department of Justice last week on the condition that Humana will divest Arcadian’s Medicare Advantage business in 51 counties in five states, namely, Arizona, Arkansas, Louisiana, Oklahoma and Texas. The divestitures are aimed at preventing monopoly in the states where the merging entities were the chief rivals before the acquisition, and hence, a union would leave virtually no competition. Humana plans to complete the divestitures by January 1, 2013.

California-based Arcadian is a privately-held organization that specializes in providing high-quality health care services to its members, most of whom dwell in small and medium-sized communities. The company provides Medicare Advantage coverage to about 62,600 people in 15 U.S. states.

The acquisition will boost Humana’s enrollment by only 50,000 members as a result of the members lost due to the mandatory divestitures. The company is already the fifth-largest health insurer in the U.S. on enrollment basis. The top two contenders of this list are WellPoint Inc. (WLP - Analyst Report) and UnitedHealth Group Inc. (UNH - Analyst Report)

Humana has a highly profitable Medicare business, which the company plans to expand further through acquisitions and joint ventures. The company completed the acquisition of California-based MD Care in January 2012, which boosted the number of its Medicare Advantage policyholders by almost 15,000.

Moreover, the Medicare Part D Prescription Drug Plan (PDP), launched in collaboration with Wal-Mart Stores in October 2010, expanded Humana’s individual Medicare stand-alone PDP membership by 52.1% to 2.54 million at the end of 2011, compared with 1.67 million at 2010 end.

Humana also forged an alliance with CNO Financial Group Inc.’s (CNO - Analyst Report) subsidiary - Bankers Life and Casualty Company - in September 2011, to offer its Medicare products. This collaboration as well as the Humana Walmart-PDP have enhanced Humana’s membership in prescription coverage plans and mail-order drug business.

Humana carries a Zacks #3 Rank, which translates into a short-term ‘Hold’ rating. We also maintain a long-term ‘Neutral’ recommendation on the company.

Email Print Share Rate Pos Rate Neg

Read/Post Comments (0) | Recommended this article (0)

Please login to Zacks.com or register to post a comment.

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.